Ceribell vs Electromed
CBLL and ELMD side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CBLL and ELMD compare
Ceribell is the larger company, worth 5.1 times as much as Electromed ($1.1B against $209M).
Ceribell grew revenue faster over the last twelve months (31.7% versus 14.1% for Electromed).
Electromed keeps more of each dollar of sales as profit, with a net margin of 15.8% compared with −64.7% at Ceribell.
Electromed scores higher on the StockData Score (21 against 6 for Ceribell), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CBLL | ELMD |
|---|---|---|
| Size and price | ||
| Market cap | $1.1B | $209M |
| Share price | $27.80 | $24.96 |
| Change, 1 year | 136% | 2.7% |
| Change, 5 years | – | 112% |
| Beta (5Y) | 0.84 | 0.50 |
| Employees | 327 | 197 |
| StockData Score | ||
| Total score | 6 | 21 (better) |
| Valuation score | 0 | 5 (better) |
| Growth score | 3 | 5 (better) |
| Performance score | 0 | 5 (better) |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 18.1× |
| P/S | 10.5× | 2.8× (better) |
| P/B | 8.3× | 4.0× (better) |
| EV/EBITDA | – | 13.1× |
| P/FCF | – | 24.0× |
| PEG | – | 0.34 |
| FCF yield | −5.1% | 4.2% (better) |
| Fair value | $11.11 | $34.08 |
| Margin of safety | −150% | 26.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 31.7% (better) | 14.1% |
| Revenue growth, 5Y average | – | 15.6% |
| Net income growth (TTM) | – | 45.5% |
| EPS growth (TTM) | – | 48.4% |
| EPS growth, 5Y average | – | 36.9% |
| Profitability | ||
| Gross margin | 88.9% (better) | 79.0% |
| Operating margin | −68.6% | 19.5% (better) |
| Net margin | −64.7% | 15.8% (better) |
| FCF margin | −53.7% | 11.5% (better) |
| Return on equity | −43.9% | 24.5% (better) |
| Return on invested capital | −331% | 34.3% (better) |
| Financial health | ||
| Debt / equity | 0.16 (better) | 0.00 |
| Interest coverage | −38.6× | – |
| Current ratio | 9.18 (better) | 7.19 |
| Altman Z-score | 14.89 | 18.06 (better) |
| Piotroski F-score | 3 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 3.5% |
| Shareholder yield | 0.00% | 3.5% (better) |
| Ownership | ||
| Held by institutions | 79.5% | 55.6% |
| Held by insiders | 26.7% | 11.4% |
| Insider net buying, 12 months | −$22.4M | −$2.2M (better) |
| Short interest, % of float | 7.0% | 2.4% |
Go deeper
- CBLL stock overview
- CBLL income statement
- CBLL valuation and score
- ELMD stock overview
- ELMD income statement
- ELMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.